Literature DB >> 22079287

5-Hydroxy-eicosapentaenoic acid is an endogenous GPR119 agonist and enhances glucose-dependent insulin secretion.

Ryouta Kogure1, Kazuya Toyama, Shuichi Hiyamuta, Itaru Kojima, Shigeki Takeda.   

Abstract

GPR119 is one of the G-protein-coupled receptors expressed in pancreatic β-cells and intestinal endocrine cells. Since agonists to GPR119 stimulate glucose-dependent insulin secretion, GPR119 agonists are anticipated to promote anti-diabetic effects and control of glucose homeostasis. Here, we reported that an omega-3 unsaturated fatty acid metabolite, 5-hydroxy-eicosapentaenoic acid (5-HEPE), was a potent agonist for GPR119 and enhanced glucose-dependent insulin secretion. 5-HEPE stimulated cAMP accumulation in mouse MIN6 insulinoma cells and human HuTu80 intestinal adenocarcinoma cells. These effects were blunted by GPR119-specific siRNA. Recombinant GPR119 also responded to 5-HEPE as well as authentic agonists. Several previous reports have indicated the beneficial biological effects of omega-3 unsaturated fatty acids, and epidemiological studies have suggested that these fatty acids plays a protective role against diabetes. However, the molecular pharmacology and receptor identifications of omega-3 unsaturated fatty acids and their metabolites have not yet been well investigated. It is hoped that our findings will encourage novel investigations into the molecular relationships between omega-3 fatty acids and diabetes.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22079287     DOI: 10.1016/j.bbrc.2011.10.141

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  23 in total

1.  Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements.

Authors:  Melinda S Schaller; Greg J Zahner; Warren J Gasper; William S Harris; Michael S Conte; Nancy K Hills; S Marlene Grenon
Journal:  J Clin Lipidol       Date:  2017-06-24       Impact factor: 4.766

2.  Hydroxyeicosapentaenoic acids and epoxyeicosatetraenoic acids attenuate early occurrence of nonalcoholic fatty liver disease.

Authors:  Chunjiong Wang; Wenli Liu; Liu Yao; Xuejiao Zhang; Xu Zhang; Chenji Ye; Hongfeng Jiang; Jinlong He; Yi Zhu; Ding Ai
Journal:  Br J Pharmacol       Date:  2017-06-09       Impact factor: 8.739

3.  Structural basis for constitutive activity and agonist-induced activation of the enteroendocrine fat sensor GPR119.

Authors:  M S Engelstoft; C Norn; M Hauge; N D Holliday; L Elster; J Lehmann; R M Jones; T M Frimurer; T W Schwartz
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

Review 4.  Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs.

Authors:  Melissa Gabbs; Shan Leng; Jessay G Devassy; Md Monirujjaman; Harold M Aukema
Journal:  Adv Nutr       Date:  2015-09-15       Impact factor: 8.701

5.  Integrated metabolomics reveals altered lipid metabolism in adipose tissue in a model of extreme longevity.

Authors:  Justin Darcy; Yimin Fang; Samuel McFadden; Matthew D Lynes; Luiz O Leiria; Jonathan M Dreyfuss; Valerie Bussburg; Vladimir Tolstikov; Bennett Greenwood; Niven R Narain; Michael A Kiebish; Andrzej Bartke; Yu-Hua Tseng
Journal:  Geroscience       Date:  2020-07-06       Impact factor: 7.713

6.  Discovery of 5-methyl-2-(4-((4-(methylsulfonyl)benzyl)oxy)phenyl)-4-(piperazin-1-yl)pyrimidine derivatives as novel GRP119 agonists for the treatment of diabetes and obesity.

Authors:  Jinying Chen; Zitai Sang; Lu Li; Linhong He; Liang Ma
Journal:  Mol Divers       Date:  2017-06-27       Impact factor: 2.943

Review 7.  Targeting lipid GPCRs to treat type 2 diabetes mellitus - progress and challenges.

Authors:  Julien Ghislain; Vincent Poitout
Journal:  Nat Rev Endocrinol       Date:  2021-01-25       Impact factor: 43.330

8.  Comparison of free serum oxylipin concentrations in hyper- vs. normolipidemic men.

Authors:  Jan Philipp Schuchardt; Simone Schmidt; Gaby Kressel; Hua Dong; Ina Willenberg; Bruce D Hammock; Andreas Hahn; Nils Helge Schebb
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2013-05-19       Impact factor: 4.006

9.  Molecular matchmaking between the popular weight-loss herb Hoodia gordonii and GPR119, a potential drug target for metabolic disorder.

Authors:  Shuyong Zhang; Yuyong Ma; Jing Li; Junjun Ma; Biao Yu; Xin Xie
Journal:  Proc Natl Acad Sci U S A       Date:  2014-09-22       Impact factor: 11.205

Review 10.  Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease.

Authors:  Jianan Zhao; Yu Zhao; Yiyang Hu; Jinghua Peng
Journal:  Cell Mol Biol Lett       Date:  2021-07-07       Impact factor: 5.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.